CytRx to Hold Conference Call

CytRx Corporation today announced that an investment-community conference call has been scheduled for Wednesday, September 6, 2006, beginning at 4:15 p.m. Eastern Time (1:15 p.m. Pacific Time) to discuss CytRx's August 29 announcement of its receipt of $24.5 million in a non-dilutive royalty agreement with the privately funded ALS Charitable Remainder Trust to fund continued development of CytRx's lead small molecule drug candidate arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS). The ALS Charitable Remainder Trust, under which The Greater Los Angeles Chapter of The ALS Association (ALSA-GLAC) is the charitable remainder beneficiary, will receive a one percent royalty payment from potential worldwide sales of arimoclomol for the treatment of ALS.

Participating on the call will be CytRx President and CEO Steven A. Kriegsman; CytRx Senior Vice President of Drug Development Jack Barber, Ph.D.; and ALSA-GLAC President and CEO Fred Fisher. Individuals interested in participating in the conference call may do so by dialing 888-803-7396 for domestic callers, or 706-634-1052 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's Web site at

write your comments about the article :: 2006 Exhibition News :: home page